Registered outcomes39

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 20 of 39

List	Outcome	Time frame	Description
Primary	Change in Hemoglobin A1c (HbA1c)	Through 36 weeks of exposure to mibavademab	Part A
Primary	Percent change in fasting Triglycerides (TG)	Through 36 weeks of exposure to mibavademab	Part A
Primary	Occurrence of Treatment Emergent Adverse Events (TEAEs)	Up to 15 months	Part B
Primary	Severity of TEAEs	Up to 15 months	Part B
Primary	Concentrations of total mibavademab in serum	Up to 15 months	Part B
Secondary	Change in HbA1c compared to placebo	From baseline to week 20	Part A
Secondary	Change in HbA1c compared to placebo	From week 56 to week 64	Part A
Secondary	Change in HbA1c	From baseline to week 52	Part B
Secondary	Percent change in fasting TG compared to placebo	From baseline to week 20	Part A
Secondary	Percent change in fasting TG compared to placebo	From week 56 to week 64	Part A
Secondary	Percent change in fasting TG	From baseline to week 52	Part B
Secondary	Occurrence of HbA1c <7%	At week 20	Part A
Secondary	Occurrence of HbA1c <7%	Through 36 weeks of exposure to mibavademab	Part A
Secondary	Occurrence of HbA1c <6.5%	At week 20	Part A
Secondary	Occurrence of HbA1c <6.5%	Through 36 weeks of exposure to mibavademab	Part A
Secondary	Occurrence of fasting TG <500 mg/dL	At week 20	Part A
Secondary	Occurrence of fasting TG <500 mg/dL	Through 36 weeks of exposure to mibavademab	Part A
Secondary	Occurrence of fasting TG <200 mg/dL	At week 20	Part A
Secondary	Occurrence of fasting TG <200 mg/dL	Through 36 weeks of exposure to mibavademab	Part A
Secondary	Occurrence of fasting TG <150 mg/dL	At week 20	Part A

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT07220785/registered